Pharmaceutical companies have finally begun to use England’s £340m ($425m) Innovative Medicines Fund (IMF), more than a year after the scheme was first launched. Alexion’s Kanuma (sebelipase alfa) is the most recent of three drugs to be accepted for National Health Service funding via the IMF.
Kanuma was recommended by England’s health technology assessment (HTA) body, NICE, for the treatment of patients with Wolman disease, an...







